Join Ascletis Pharma to discuss the Company's next-generation obesity portfolio including clinical updates onits potential best-in-class oral small molecule GLP-1 receptor agonist (ASC30) tablets, once monthly and once quarterly ultra-long-acting subcutaneous depot formulations of ASC30 and its ultra long acting once monthly peptides for obesity.

Jinzi Jason Wu, Ph.D., Founder, Chairman and CEO, and John Gargiulo, MBA, Chief Business Officer, will host Q&A immediately following the presentation. Ascletis Pharma is an innovative R&D driven biotech listed on the Hong Kong Stock Exchange (1672.HK).